Released Aug 6, 2025, after the close
10-Q filed Aug 6, 2025, 37 days after period end · 0000950170-25-104060
Q2 2025 · 10-Q
Revenue$9.63M$9.63M +12.8% vs Q2 2024+2.2% vs Q1 2025
Net Income-$10.20M-$10.20M N/M vs Q2 2024N/M vs Q1 2025
EPS Diluted-$1.33-$1.33 N/M vs Q2 2024N/M vs Q1 2025
Operating Income-$11,093,000N/M
Operating Cash Flowderived-$16,758,000N/M
Free Cash Flowderived-$16,758,000N/M
Margins · derived
Operating margin-115.2%+27.8 pt vs Q2 2024
Net margin-105.9%+24.8 pt vs Q2 2024
What the release said
The release
Same quarter
| Metric | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 |
|---|---|---|---|---|
| Revenue | $9.63M | $8.53M | $0.00 | — |
| Net Income | -$10.20M | -$11.15M | -$16.90M | -$24.46M |
| EPS Diluted | -$1.33 | -$1.98 | -$3.88 | -$0.51 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR